Treatment for Ertapenem Infiltration
Stop the infusion immediately, disconnect the IV line, and elevate the affected extremity; apply warm compresses to the site and monitor closely for progression, as ertapenem infiltration is managed supportively without specific antidotes.
Immediate Management Steps
When ertapenem infiltration occurs, take the following actions:
- Discontinue the infusion immediately and remove the IV catheter
- Aspirate any residual drug from the IV site if possible before removing the catheter
- Elevate the affected extremity above heart level to reduce edema
- Apply warm compresses to the infiltrated area to promote vasodilation and drug dispersion
- Mark the borders of the affected area with a pen to monitor progression
- Document the extent of infiltration including volume extravasated (if known), appearance, and patient symptoms
Mechanism of Injury
Ertapenem causes tissue injury through pH-mediated and osmolar mechanisms 1. The reconstituted solution has properties that can cause local tissue irritation, edema, and potentially tissue damage if significant volumes extravasate. The FDA label notes that infused vein complications occurred in 7.1% of patients receiving ertapenem, and phlebitis/thrombophlebitis has been reported 2.
Monitoring Requirements
- Assess the site every 1-2 hours for the first 24 hours for signs of progression (increasing erythema, induration, blistering, or necrosis)
- Monitor for compartment syndrome if infiltration involves a large volume, particularly in the forearm or lower leg
- Check distal neurovascular status (pulses, sensation, motor function, capillary refill)
- Photograph the site at baseline and during follow-up for documentation
When to Escalate Care
Obtain immediate surgical consultation if you observe:
- Progressive tissue necrosis or skin sloughing
- Signs of compartment syndrome (severe pain, tense swelling, paresthesias, diminished pulses)
- Blistering or full-thickness skin injury
- Functional impairment of the affected extremity
No Specific Antidote Available
Unlike vasopressor extravasations (which can be treated with phentolamine or terbutaline) or hypertonic solutions (which may benefit from hyaluronidase), ertapenem infiltration has no pharmacological antidote 1. Management is entirely supportive, focusing on limiting tissue exposure and promoting drug dispersion.
Prevention Strategies
To minimize future risk:
- Infuse ertapenem over 30 minutes as specified in the FDA label 2
- Avoid small, fragile veins and consider using larger peripheral veins or central access for prolonged therapy
- Monitor the IV site closely during infusion for early signs of infiltration (swelling, pain, blanching)
- The FDA label specifically warns about caution with intramuscular administration to avoid inadvertent vascular injection 2, and similar vigilance applies to IV administration
Alternative Administration Routes
If peripheral IV access is problematic and infiltration risk is high, consider:
- Subcutaneous administration has been studied and shows 99% bioavailability, though with delayed peaks 3, 4
- Central venous access for patients requiring prolonged therapy (up to 14 days per FDA label) 2
Common Pitfall
Do not apply ice or cold compresses to ertapenem infiltration sites, as this causes vasoconstriction and may worsen tissue injury by trapping the drug locally. Warm compresses are preferred to enhance drug dispersion through vasodilation 1.